Skip to main content

What is the success rate of Breyanzi?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on March 31, 2025.

Official Answer by Drugs.com

The success rate of Breyanzi (lisocabtagene maraleucel) varies depending on the condition being treated. Clinical trial data show that complete response rates range from 20% to 73% across different types of lymphoma and leukemia.

Below are clinical trial results for Breyanzi in various conditions, with some patients experiencing partial response to treatment.

Large B-cell lymphoma

Breyanzi was studied in over 250 adults with refractory or relapsed B-cell lymphoma in a multicenter clinical trial. The study showed:

Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

The complete response rate among patients who took Breyanzi for relapsed or refractory CLL or SLL in a clinical trial called TRANSCEND-CLL was 20%. A total of 65 patients were treated with Breyanzi in the study.

Related questions

Follicular lymphoma

In the TRANSCEND-FL clinical trial, adults with relapsed or refractory follicular lymphoma who took Breyanzi had a complete response rate of 73.4%. A total of 94 patients that were treated with Breyanzi were included in the final results. In order to be considered to have complete response, patients who did not have a negative bone marrow biopsy between their most recent disease progression and before starting lymphodepleting chemotherapy were required to have a negative bone marrow biopsy.

Mantle cell lymphoma

Out of 68 patients with relapsed or refractory mantle cell lymphoma who were treated with Breyanzi in the TRANSCEND-MCL trial, 67.6% saw a complete response.

Individual responses to Breyanzi vary, and partial responses were also observed in these trials. Speak with your healthcare provider to understand how these results may apply to your specific situation.

References

Breyanzi [package insert]. Updated May 2024. Juno Therapeutics, Inc. Accessed August 6, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed

U.S. Food and Drug Administration. 2021. FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma. Accessed August 6, 2024 at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-or-refractory-large-b-cell-lymphoma

U.S. Food and Drug Administration. 2024. FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lisocabtagene-maraleucel-follicular-lymphoma

U.S. Food and Drug Administration. 2024. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma. Accessed August 6, 2024 at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma

Read next

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).

Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading

Does Truxima make you gain weight?

Weight gain has been reported in 11% of patients being treated with Truxima (rituximab) for non-Hodgkin’s lymphoma (NHL). Be sure to contact your doctor right away if you have a rapid or unexplained weight gain or fluid retention (edema), nausea, vomiting, diarrhea, or lack of energy when using Truxima, as you may need immediate medical care. Continue reading

What causes infusion reactions to rituximab?

Rituximab infusion reactions are caused primarily by cytokine release in the body. Cytokines are immune system proteins in the body that help to fight infections but can cause an inflammatory response. Infusion reactions may cause hives, itching, shortness of breath, chest pain or dizziness and are a very common side effect of treatment with rituximab (Rituxan). Continue reading

See also:

Related medical questions

Drug information

Related support groups